[{"orgOrder":0,"company":"TLC BioSciences","sponsor":"Strides Pharma Science","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Miscellaneous","year":"2021","type":"Partnership","leadProduct":"Amphotericin B","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"TLC BioSciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"TLC BioSciences \/ Strides Pharma Science","highestDevelopmentStatusID":"15","companyTruncated":"TLC BioSciences \/ Strides Pharma Science"},{"orgOrder":0,"company":"TLC BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"TAIWAN","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"TLC BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"TLC BioSciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"TLC BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"TLC BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ropivacaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase III","graph3":"TLC BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"TLC BioSciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"TLC BioSciences \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by TLC BioSciences

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          COMPAMED
                          Not Confirmed
                          COMPAMED
                          Not Confirmed

                          Details : Ropivacaine HCl is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Pain, Postoperative.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 30, 2025

                          Lead Product(s) : Ropivacaine Hydrochloride

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          COMPAMED
                          Not Confirmed
                          COMPAMED
                          Not Confirmed

                          Details : Results showed that TLC599 (Dexamethasone Sodium Phosphate), a proprietary BioSeizer, demonstrated statistically significantly greater reduction in WOMAC pain and function as well as VAS scores compared to placebo through 24 weeks.

                          Product Name : Undisclosed

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          March 07, 2022

                          Lead Product(s) : Dexamethasone Sodium Phosphate

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          COMPAMED
                          Not Confirmed
                          COMPAMED
                          Not Confirmed

                          Details : The partnership aims to support the TLC for the launch and commercialization of their lead product AmphoTLC (amphotericin B) in India. It will be indicated for the COVID-19-associated mucormycosis cases.

                          Product Name : AmphoTLC

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          March 19, 2021

                          Lead Product(s) : Amphotericin B

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Strides Pharma Science

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank